P

Inventor

FINKELSTEIN NINA

IL27 patents
⚠️ This page may combine multiple inventors who share the name “FINKELSTEIN NINA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

TEVA PHARMA

25 patents
US7060833B2Jun 13, 2006

Substantially pure cilostazol and processing for making same

TEVA PHARMA11 citations92
US6515128B2Feb 4, 2003

Processes for preparing cilostazol

TEVA PHARMA20 citations92
US6281381B1Aug 28, 2001

Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

TEVA PHARMA18 citations92
US5646188AJul 8, 1997

Polyamine derivatives of 1-aminoindan

TEVA PHARMA46 citations91
US6825214B2Nov 30, 2004

Substantially pure cilostazol and processes for making same

TEVA PHARMA11 citations82
US6963008B2Nov 8, 2005

Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

TEVA PHARMA8 citations74
US6696601B2Feb 24, 2004

Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

TEVA PHARMA11 citations74
US7067669B2Jun 27, 2006

Substantially pure cilostazol and processes for making same

TEVA PHARMA5 citations73
US7064208B2Jun 20, 2006

Substantially pure cilostazol and processes for making same

TEVA PHARMA5 citations73
US6909004B2Jun 21, 2005

Method for the purification of lansoprazole

TEVA PHARMA5 citations73
US7692008B2Apr 6, 2010

Reference standard for characterization of rosuvastatin

TEVA PHARMA2 citations62
US7692010B2Apr 6, 2010

Reference standard for characterization of rosuvastatin

TEVA PHARMA2 citations62
US7692009B2Apr 6, 2010

Reference standard for characterization of rosuvastatin

TEVA PHARMA2 citations62
US7244844B2Jul 17, 2007

Reference standard for characterization of rosuvastatin

TEVA PHARMA2 citations62
US7060837B2Jun 13, 2006

Method for the purification of lansoprazole

TEVA PHARMA3 citations62
US7022859B2Apr 4, 2006

Method for the purification of lansoprazole

TEVA PHARMA2 citations62
US6777554B2Aug 17, 2004

Preparation of N-methylparoxetine and related intermediate compounds

TEVA PHARMA3 citations62
US6576764B2Jun 10, 2003

Synthesis and crystallization of piperazine ring-containing compounds

TEVA PHARMA2 citations62
US6545149B2Apr 8, 2003

Synthesis and crystallization of piperazine ring-containing compounds

TEVA PHARMA3 citations62
US7507829B2Mar 24, 2009

Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates

TEVA PHARMA3 citations60
US7741482B2Jun 22, 2010

Reference standard for characterization of rosuvastatin

TEVA PHARMA0 citations52
US7674923B2Mar 9, 2010

Process for preparing forms of atorvastatin calcium substantially free of impurities

TEVA PHARMA0 citations52
US7622588B2Nov 24, 2009

Method for the purification of lansoprazole

TEVA PHARMA0 citations51
US7915423B2Mar 29, 2011

Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates

TEVA PHARMA1 citations50
US7683177B2Mar 23, 2010

Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole

TEVA PHARMA0 citations50

FINKELSTEIN NINA

2 patents